Our Articles
Explore our thought leadership article library, where you can find a wealth of insights on regulatory intelligence, industry updates, and the latest pharmaceutical and biotechnology developments.
Immunogenicity of Innovative and Biosimilar Medicinal Products
The first regulation and guidance for copy biotech products (biosimilars), pioneered by the EMA, not only enabled the introduction of biosimilars in the EU, but also were a model for regulatory regions worldwide.
Regulatory Intelligence - Year Round Up
An overview of the key regulatory intelligence updates from FDA, EC, EMA & MHRA released in 2023.
Reform of EU Medicines Legislation: A Blessing or a Missed Opportunity?
Ideally, all patients in the European Union should have equal access to safe, efficacious, and high-quality medicines. However, reality is more erratic, as many European citizens are all too familiar with the frustration of limited access to medicines.
11th Annual MIBio Conference
Scendea is pleased to share our experience at the 11th annual MIBio conference, a gathering of experts in the fields of biologics formulations and drug delivery. The conference served as a platform for illuminating discussions on the stability of biopharmaceuticals.
The Future of UK Regulation: Driving innovation in the Life Sciences
This October, Scendea’s Principal Consultant, Ian Waterson, had the pleasure of attending the UK BioIndustry Association (BIA) conference on The Future of UK Regulation: Driving innovation in the Life Sciences.
Microbiome Medicinal Products: Concept to Commercial
A growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest.
Micro, Small and Medium-sized Enterprise Status in the EU and UK
Micro, small and medium-sized enterprises (SMEs) are valuable sources of pharmaceutical innovation. In 2020, nearly 20% of all human medicines recommended for authorisation were developed by SMEs, with half of these targeting rare diseases.
BioCentury On The Road. Amsterdam, 2023
Biocentury has helped biotech executives and investors make business critical decisions and build larger networks with peers across the innovation ecosystem. To kick of a European tour celebrating the 30th anniversary of the organisation, and in-depth interview with Emer Cooke, executive director of the European Medicines Agency was held in Amsterdam.
Vaccine Authorisation: An Overview of the Last 12 Months
Vaccines have been in the spotlight in recent years and are a hot topic. Indeed, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focus, but other vaccine development has not halted. In the last 12 months alone a number of vaccines have been authorised in the EU and U.S and are presented below and discussed in this short summary.